Hall Laurie J Trustee Sells 75 Shares of Amgen Inc. (NASDAQ:AMGN)

Hall Laurie J Trustee trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 1.2% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 6,120 shares of the medical research company’s stock after selling 75 shares during the period. Hall Laurie J Trustee’s holdings in Amgen were worth $1,596,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMGN. Grove Bank & Trust increased its position in shares of Amgen by 3.5% during the fourth quarter. Grove Bank & Trust now owns 2,750 shares of the medical research company’s stock valued at $717,000 after acquiring an additional 93 shares during the last quarter. Brady Martz Wealth Solutions LLC bought a new position in Amgen in the 4th quarter valued at $1,245,000. My Legacy Advisors LLC increased its position in shares of Amgen by 5.0% during the 4th quarter. My Legacy Advisors LLC now owns 3,065 shares of the medical research company’s stock valued at $824,000 after purchasing an additional 147 shares during the last quarter. Steigerwald Gordon & Koch Inc. raised its stake in shares of Amgen by 0.6% during the 4th quarter. Steigerwald Gordon & Koch Inc. now owns 70,450 shares of the medical research company’s stock worth $18,362,000 after purchasing an additional 434 shares during the period. Finally, Liberty One Investment Management LLC boosted its holdings in shares of Amgen by 9.3% in the 4th quarter. Liberty One Investment Management LLC now owns 14,895 shares of the medical research company’s stock worth $3,882,000 after buying an additional 1,264 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

NASDAQ AMGN opened at $272.11 on Monday. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a fifty day moving average of $273.95 and a 200-day moving average of $307.20. The company has a market capitalization of $146.27 billion, a P/E ratio of 34.84, a P/E/G ratio of 2.68 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company’s revenue was up 23.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.96 earnings per share. As a group, equities research analysts predict that Amgen Inc. will post 19.57 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.50%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. Amgen’s payout ratio is presently 115.24%.

Wall Street Analyst Weigh In

Several brokerages have commented on AMGN. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $405.00 price objective on shares of Amgen in a research report on Tuesday, October 22nd. UBS Group dropped their price objective on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, October 31st. Bank of America reissued an “underperform” rating and issued a $256.00 target price on shares of Amgen in a research report on Tuesday, December 10th. Piper Sandler dropped their price target on Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a research report on Thursday, January 2nd. Finally, StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $314.91.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.